BioSpace News Archive

- ARS Pharmaceuticals’ lead product, ARS-1 (epinephrine nasal spray) to treat severe allergic reactions, has previously been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) - Neurelis’ lead product, VALTOCO® (diazepam nasal spray), approved by the FDA for seizure cluster rescue, also utilizes Intravail® as a key component of its formulation - New data further highlight the permeation enhancement potency of Intravail® for both small and large mole

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the achievement of key recruitment milestones in the ProActive registry study and success in the Prospera early access program.

COVID-19 dashboard provides real-time laboratory data and hospital bed management for accurate monitoring and case reporting

Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. At the beginning of the COVID-19 outbreak, Junshi Biosciences—a China-based biopharmaceutical company specializing in discovery, development and commercialization of

A new study published in The Journal of Infectious Diseases showed high rates of GBS infection among the elderly, African Americans, and people with chronic conditions

Company Launches #INKEDforALS Campaign in its Commitment to Raising Awareness for the ALS Community During ALS Awareness Month

Eve & Co Incorporated is pleased to announce that Health Canada has approved an amendment to the licence of its wholly-owned subsidiary, Natural MedCo Ltd., permitting the use of a 7,300 square foot area as eleven additional processing rooms.

Krystal Biotech reported financial results and key operational progress updates for the first quarter ending March 31, 2020.

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Paul Stickler as the company’s new Senior Vice President of Sales and Marketing. Stickler brings more than twenty-five years of pharmaceutical sales and marketing experience with a primary focus in orphan and neurology products. In the new role, he will be responsi

-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment -- REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported results from a long-term open-label extension (OLE) study of antolimab for the tre